Moderna recently gave investors a momentary scare as its stock experienced a sharp, sudden plunge on Thursday. Yet, even with that pullback, the company remains one of the standout performers in the biotech sector this year. Nor is Moderna standing alone; the broader biotechnology sector is currently on a remarkable roll, supported by strong momentum that points toward the possibility of further market gains ahead.<\/p>\n
The iShares Biotechnology ETF (IBB) has climbed 24% through October 23, extending a robust 28% gain achieved over the course of 2025. Impressively, two dozen of the exchange-traded fund’s 233 individual holdings have more than doubled in value on a year-to-date basis. Moderna leads this elite pack with an astonishing 587% surge, and that stellar performance comes even after an 18% single-day decline following an accidental leak of clinical data concerning its experimental cancer vaccine\u2014data that Wall Street analysts ultimately confirmed was quite positive.<\/p>\n
Market observers and industry experts note that a brand-new biotech cycle is clearly underway. This resurgence is being vigorously fueled by a combination of strong clinical trial results, aggressive mergers and acquisitions activity, and breakthroughs in advanced technologies like genomics, mRNA platforms, and artificial intelligence.<\/p>\n
"We’re in the midst of a powerful innovation cycle," said John Hall, portfolio manager of the T. Rowe Price Biotechnology ETF. "What’s super exciting is we’re seeing newer modalities start to make it to market." Companies "understand the disease biology better," he added, a factor that could ultimately lead to an even greater number of novel, highly targeted drugs successfully clearing regulatory hurdles and reaching patients.<\/p>\n
Investor enthusiasm is running high for platform technologies such as mRNA and genomics, propelled further by a steady, reliable stream of new drug approvals. The Food and Drug Administration approved approximately a dozen novel biologic drugs in 2025 out of 46 total approvals for the year. Looking ahead, roughly 66 novel drugs are currently sitting in the pipeline awaiting FDA approval decisions. This upcoming cohort includes potential commercial blockbusters, such as the collaborative cancer treatment from Moderna and Merck designed for melanoma, alongside a promising next-generation obesity treatment from pharmaceutical giant Eli Lilly.<\/p>\n
Industry analysts emphasize that artificial intelligence could also pave the way for accelerated regulatory approvals as healthcare and pharmaceutical companies widely deploy specialized software to streamline and speed up the arduous drug development lifecycle.<\/p>\n
"Biotech is a phenomenal application for artificial intelligence and machine learning," said Piper Sandler analyst Ted Tenthoff. "You can set up exciting predictive models that, frankly, can do things that we’ve never been able to do in the space in terms of novel drug discovery."<\/p>\n
Admittedly, the industry is only recently recovering from an extended, difficult fallow period. The sector’s previous era of stellar performance coincided with the Covid-19 pandemic, a time when ultra-low interest rates encouraged heavy investment into early-stage drug developers, and widespread demand for mRNA vaccines fueled an unprecedented revenue boom for companies like Moderna, Pfizer, and BioNTech.<\/p>\n
Following that unique window, the sector turned distinctly cold as many underfunded early-stage companies fizzled out. Demand for Covid-related vaccines largely evaporated, while rapidly surging interest rates threw a heavy chill over initial public offerings and corporate dealmaking. <\/p>\n
Naturally, the inherent risks of the industry have not vanished. Biotechnology remains a sector where products typically require many years of expensive research and development, historically resulting in far more clinical failures than commercial successes. Nevertheless, analysts point out that the underlying health of the industry is fundamentally stronger today. While that improved health is clearly reflected in strong share price performances and richer market valuations, financial experts argue that compelling reasons to invest in the space remain firmly intact.<\/p>\n
Recent clinical trial results are stoking widespread excitement that novel therapies currently moving through the pipeline could successfully tackle some of the most difficult and intractable problems in modern medicine.<\/p>\n
The experimental melanoma drug being developed jointly by Moderna and Merck, for instance, utilizes mRNA technology to trigger a targeted immune response in patients. It focuses on tumors that have already been surgically removed and genetically analyzed. While it functions differently than a traditional preventive vaccine, it applies a very similar immunological mechanism. In combination with Merck\u2019s established cancer drug Keytruda, the therapy demonstrated a 42% reduction in the risk of cancer recurrence or death.<\/p>\n
Although initial Phase 3 results prompted a brief wave of disappointment on Wall Street regarding specific efficacy metrics, practicing oncologists emphasized that the clinical outcomes were still profoundly positive. Medical professionals view the technology as a potential game-changer capable of ushering in a brand-new era of personalized treatments across a wide variety of cancers. Both Moderna and Merck have publicly stated their intention to submit the drug for formal FDA review with the goal of securing a commercial launch by 2027.<\/p>\n
Inflammation treatment represents another exceptionally promising clinical arena. AstraZeneca and Amgen recently released positive Phase 3 results evaluating a new indication for their drug Tezspire, an injectable therapeutic already approved to treat severe asthma and nasal polyps. In recent clinical trials, the therapy successfully relieved debilitating swallowing symptoms while healing both microscopic and visually identifiable tissue damage in patients suffering from severe eosinophilic esophagitis, a painful inflammatory condition of the throat.<\/p>\n
Meanwhile, pharmaceutical major Roche recently notched a significant regulatory win after the FDA approved its drug Enspryng to treat rare inflammatory and autoimmune diseases. The decision made the therapy the first and only at-home injectable treatment available for adult patients suffering from thyroid eye disease.<\/p>\n
Obesity therapeutics are also advancing rapidly beyond the first generation of GLP-1 receptor agonists. Eli Lilly\u2019s experimental treatment retatrutide, classified as a "triple agonist" because it targets three distinct hormone receptors simultaneously, successfully cleared two additional clinical trials over the summer. The drug produced an impressive 28% to 30% reduction in body weight at its highest doses during the studies, according to company disclosures. Eli Lilly has confirmed that it plans to officially submit retatrutide for FDA approval during the first quarter of 2027.<\/p>\n
A substantial portion of the ongoing innovation within the sector is occurring outside traditional drug manufacturing, specifically thriving in areas like advanced gene sequencing, specialized mRNA infrastructure, and high-tech laboratory instruments.<\/p>\n
Illumina has seen its stock price more than double over the course of the year. The prominent DNA and gene sequencing enterprise is experiencing accelerating customer demand for its high-end NovaSeq X sequencing platform. Major pharmaceutical firms, including Bristol-Myers Squibb, Merck, and Kura, are actively collaborating with Illumina to develop cutting-edge precision oncology solutions.<\/p>\n
Another major market winner is 10x Genomics, which has seen its share price advance by more than 300%. The specialized biotech firm supplies sophisticated laboratory instruments that help academic and corporate scientists research complex disease areas such as oncology, immunology, and neuroscience. The company\u2019s Atera platform is actively assisting in the production of massive biological data sets used to train artificial intelligence models, a computational process that helps dramatically accelerate the creation of personalized therapies.<\/p>\n
On the broader artificial intelligence front, industry leaders note that the technology is transforming corporate efficiency. According to Shreef\u00e4l Mehta, president of Guidant BioTherapeutics, companies are utilizing AI to navigate the pipeline more efficiently. Using AI tools, "you can now bring a drug to clinical trials with less capital. More investment is also going into companies that are demonstrating that," he noted.<\/p>\n
The global market for artificial intelligence in drug discovery is projected to grow substantially, expanding from an estimated $20 billion market in 2025 to more than $160 billion by 2035, according to comprehensive forecasts published by research and consulting firm Towards Health.<\/p>\n
Another powerful catalyst supporting the biotechnology sector is the steady resurgence of mergers and acquisitions. Dealmaking activity across the biopharma landscape reached a staggering $134 billion during the first half of 2026 alone, easily surpassing the $112 billion recorded for the entirety of 2025, notes Jeet Mukherjee, a biotechnology analyst at BTIG. This high volume of corporate transactions serves as a positive underlying signal, indicating that a greater number of developmental-stage drugs are demonstrating undeniable clinical promise.<\/p>\n
Corporate dealmaking is also being driven by the looming "patent cliff" facing major pharmaceutical companies. Brand-name products representing approximately $180 billion in annual revenue are slated to lose market exclusivity and patent protection by 2030, according to research compiled by the RTW Institute. Large enterprises confronting these impending revenue expirations "are looking for novel products and innovative products to put into their pipeline," Mehta explained.<\/p>\n
Furthermore, massive commercial successes derived from GLP-1 blockbusters have left several major players exceptionally flush with cash, providing ample dry powder for strategic acquisitions. Eli Lilly alone has completed roughly 10 distinct acquisition deals throughout 2026, totaling a combined investment of $25 billion.<\/p>\n
Investors seeking exposure to these industry trends often turn to sector-specific exchange-traded funds, though individual funds exhibit distinct structural differences. The iShares Biotechnology ETF functions as a lower-cost option that tracks a market-cap-weighted index of established biotech stocks, led heavily by industry stalwarts such as Gilead Sciences, Amgen, Vertex Pharmaceuticals, and Moderna.<\/p>\n
Conversely, the State Street SPDR S&P Biotech ETF holds its constituent stocks in equal weight, providing investors with significantly greater exposure to smaller- and mid-cap names. Its top holdings include Moderna, Natera, Twist Bioscience, and Halozyme Therapeutics.<\/p>\n
Wall Street investment firms continue to highlight specific infrastructure plays as vital components of the life sciences arena. Analysts at Piper Sandler characterize Illumina and 10x Genomics as primary infrastructure assets, arguing that their foundational technologies are actively driving the next generation of precision medicine. Piper analyst David Westenberg maintains a buy rating on Illumina, while taking a more neutral stance on 10x Genomics as the company scales its operations.<\/p>\n
Twist Bioscience represents another notable name drawing attention from institutional investors. The company manufactures customized synthetic DNA and provides advanced DNA sequencing tools. Twist has previously partnered with Eli Lilly to utilize its AI and machine-learning platforms and established a collaboration with Anthropic to begin testing the Claude AI model for protein development applications. While consensus forecasts suggest Twist may not turn a positive earnings-per-share profit until late in the decade, annual revenues are projected to scale significantly over the coming years, driven by strong average price targets from covering analysts.<\/p>\n
Within the small-cap segment, Piper Sandler’s Tenthoff highlights Monte Rosa Therapeutics, a pioneer in targeted protein degradation that selectively destroys disease-causing proteins. The firm has successfully established a high-profile partnership with Novartis to develop novel therapies aimed at inflammatory conditions and autoimmune diseases, triggering lucrative milestone payments as clinical programs advance.<\/p>\n
BTIG\u2019s Mukherjee similarly points to small-cap clinical-stage developer Faeth Therapeutics, which is advancing a novel two-drug regimen designed to treat breast cancer and other difficult solid tumors. The experimental regimen carries the potential to address safety and dosing limitations associated with existing breast cancer therapies, positioning it as a potential future cornerstone of oncology care.<\/p>\n
Additional small-cap candidates drawing analyst interest include Kymera Therapeutics, which is developing an oral alternative to blockbuster injectable therapies like Dupixent. Because oral medications are frequently preferred by patients over injections, industry analysts believe these pipeline candidates could capture substantial market share across various immunological indications while expanding the broader addressable patient population. T. Rowe Price\u2019s Hall counts Kymera among his favored holdings for its unique ability to unlock disease targets that were previously considered completely undruggable by traditional pharmaceutical approaches.<\/p>\n","protected":false},"excerpt":{"rendered":"
Moderna recently gave investors a momentary scare as its stock experienced a sharp, sudden plunge on Thursday. Yet, even with that pullback, the company remains one of the standout performers in the biotech sector this year. Nor is Moderna standing alone; the broader biotechnology sector is currently on a remarkable roll, supported by strong momentum […]<\/p>\n","protected":false},"author":23,"featured_media":798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[1023,387,1026,30,33,31,1028,298,32,1025,1027,144,1024],"class_list":["post-799","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-global-economy","tag-biotech","tag-despite","tag-drug","tag-economy","tag-finance","tag-global","tag-jitters","tag-market","tag-markets","tag-novel","tag-pipelines","tag-sector","tag-surges"],"_links":{"self":[{"href":"https:\/\/estmakcapital.com\/index.php?rest_route=\/wp\/v2\/posts\/799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/estmakcapital.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/estmakcapital.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/estmakcapital.com\/index.php?rest_route=\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/estmakcapital.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=799"}],"version-history":[{"count":0,"href":"https:\/\/estmakcapital.com\/index.php?rest_route=\/wp\/v2\/posts\/799\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/estmakcapital.com\/index.php?rest_route=\/wp\/v2\/media\/798"}],"wp:attachment":[{"href":"https:\/\/estmakcapital.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/estmakcapital.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/estmakcapital.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}